Supplement: MilliporeSigma Sees Opportunity in Continuous Processing
From the GEN Sounds of Science Podcast
Why CAR-T Therapies Don’t Work for Everyone Yet
Selecting the Best Type of T Cells for CAR-T May be Key to the Overall Efficacy of the Therapies
Cell-Centered: Scientists Embrace Cell-Replacement Therapy for Type 1 Diabetes
Forming Beta Cells from Stem Cells
GEN Roundup: Multiplex Immunoassays Bring the Array, Not the Disarray
Get Multiplex Immunoassay Advice from GEN's Expert Panel
For full access to this article login to GEN Select now.
Innovative Drug R&D on the Rise in China
Technically Savvy Returnees, Influx of VC Funding, and Solid Government Support Buoy Efforts
- As the Chinese pharmaceutical industry expands rapidly, Chinese pharma and biotech companies—and even outsourcing service providers—are increasingly paying attention to and investing in innovative drug R&D. A flotilla of returnees and venture capital firms are aiding in these endeavors. Unfortunately, innovative R&D activities in China remain largely unknown ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.